Zobrazeno 1 - 10
of 217
pro vyhledávání: '"programmed cell death‐1 (PD‐1)"'
Autor:
Chunyan Lan, Huaiwu Lu, Lin Zhou, Kunlun Liao, Junxiu Liu, Zhiwen Xie, Haixi Liang, Guorong Zou, Ting Yang, Qin Xu, Xin Huang
Publikováno v:
Cancer Communications, Vol 44, Iss 6, Pp 654-669 (2024)
Abstract Background Camrelizumab plus apatinib have demonstrated robust antitumor activity and safety in patients with advanced cervical cancer (CLAP study; NCT03816553). We herein present the updated long‐term results of the CLAP study and explore
Externí odkaz:
https://doaj.org/article/0e9447bc32f74ee488112a4283effb55
Autor:
Shanshan (Jenny) Zhong, Xiaoling Liu, Tomonori Kaneko, Yan Feng, Owen Hovey, Kyle Yang, Sally Ezra, Soon-Duck Ha, Sung Kim, John K. McCormick, Huadong Liu, Shawn Shun-Cheng Li
Publikováno v:
Cells, Vol 13, Iss 14, p 1193 (2024)
The programmed cell death protein 1 (PD-1) plays a critical role in cancer immune evasion. Blocking the PD-1-PD-L1 interaction by monoclonal antibodies has shown remarkable clinical efficacy in treating certain types of cancer. However, antibodies ar
Externí odkaz:
https://doaj.org/article/8d0ec0841b94426d9ca564765b559f9b
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Introduction The optimal first-line immunotherapy regimen for advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients with programmed cell death ligand 1 (PD-L1) expression ≥ 50% remains unclear. Our aim is to determine the mo
Externí odkaz:
https://doaj.org/article/e0351466e20844bdacf90b847354cc82
Autor:
Ai Tsuji, Sayuri Yoshikawa, Sae Morikawa, Yuka Ikeda, Kurumi Taniguchi, Haruka Sawamura, Tomoko Asai, Satoru Matsuda
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 3, Pp 460-473 (2023)
Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However, its effectiveness is limited in part due to the loss
Externí odkaz:
https://doaj.org/article/3399d79b4953409dbb7f2383b3d968b9
Autor:
Jun Feng, Aimaiti Yasen, Tianxing Dai, Runbin Liang, Zhihong Liao, Ping He, Zhihong Lin, Guoying Wang
Publikováno v:
Liver Research, Vol 7, Iss 2, Pp 156-160 (2023)
Adenosquamous carcinoma (ASC) is a rare histological type of intrahepatic cholangiocarcinoma, which includes both adenocarcinoma and squamous cell carcinoma. The clinical features, physical examination, routine laboratory tests, and imaging examinati
Externí odkaz:
https://doaj.org/article/528853064b6d4b1ca97705cfdf32f08e
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2702-2712 (2023)
Abstract Background Recent evidence suggested a potential correlation between BMI and the efficacy of immune checkpoint inhibitors in cancer patients. This study aimed to evaluate the prognostic value of the body mass index (BMI) in recurrent/metasta
Externí odkaz:
https://doaj.org/article/d01db6c888524d4990c12f9f778a7b3b
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-9 (2022)
Key points Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with antiangiogenic therapy. Besides, PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment undergoing concurrent TAF prop
Externí odkaz:
https://doaj.org/article/f2cb7053080949dc87d5066299cb2822
Autor:
Marton Gyulai, Zsolt Megyesfalvi, Lilla Reiniger, Tunde Harko, Bence Ferencz, Luca Karsko, Laszlo Agocs, Janos Fillinger, Balazs Dome, Zoltan Szallasi, Judit Moldvay
Publikováno v:
Pathology and Oncology Research, Vol 29 (2023)
Background: Our knowledge is still limited about the characteristics and treatment of rare lung tumors. The aim of our study was to determine programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) expression in rare pulmonary tumor
Externí odkaz:
https://doaj.org/article/b9f0cf08651e45688c8a7f1f5ad9ab72
Autor:
Wei Shi, Yu Zhang, Chonghua Hao, Xiaofeng Guo, Qin Yang, Junfang Du, Yabin Hou, Gaigai Cao, Jingru Li, Haijiao Wang, Wei Fang
Publikováno v:
PeerJ, Vol 11, p e15481 (2023)
Objectives To investigate the expression and significance of programmed cell death protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1) in the mucosal tissues and peripheral blood of patients with ulcerative colitis (UC). Methods Eighty patien
Externí odkaz:
https://doaj.org/article/508ad965ec0a42428f29a40af1648b99
Autor:
Nan Zhou, Yuhong Chen, Qian Huang, Lili Jiang, Hu Liao, Hongfeng Gou, You Lu, Guowei Che, Yan Zhang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immunotherapy plus chemotherapy has been approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC, stage IV). Recently, the 2023 version of the National Comprehensive Cancer Network Guidelines recommended immunotherapy
Externí odkaz:
https://doaj.org/article/bb3ec0033d1a4d65a68ab6424161fa8f